Bio-Solutions Corp.
OTC Bulletin Board : BISU

Bio-Solutions Corp.

March 26, 2010 16:00 ET

Bio-Solutions Corp. Has Signed a Service Offer to Run Pilot Trial for GreenEx™, its Organic Anti-Malaria Insecticide

MONTRÉAL, QUÉBEC, CANADA--(Marketwire - March 26, 2010) - Bio-Solutions Corp. (OTCBB:BISU), is pleased to announce that they have signed a service offer to serve as a Pilot trial for its main product GreenEx™. 

Bio-Solutions Corp has met with local authorities In the Democratic Republic of Congo (DRC) and has confirmed a service offer, to run a pilot study of GreenEx™, in Kinshasa Congo.

"We have had such a positive response at the Municipal level, we have to go Back to Africa, to meet with higher Up Officials." stated Dr. Chaumillon.

Local governments have applied to various International funding organizations.

"As soon as the financing is secured, we will begin the trial on site. I am very confident with our supportive shareholder's , it is just a short matter of time, before this trial begins. The fact that we have to go back and meet with Provincial and Federal officials, is extremely promising" stated Dr. Chaumillon.

Bio-Solutions Corp. has received much Interest from many districts and provinces in Congo, regarding GreenEx™.

"If the trial outcome is positive, with our Organic FDA approved Insecticide, we will have opened a market estimated at more than $5 Million in annual Sales. Our Target time frame to complete this pilot trial is mid Q2 2010. These inquirers can have an exponential effect on our sales, which in turn will drive revenues. Everything I have worked for, has come to this point, I am ecstatic". said Dr. Chaumillon.

According to www.malaria.org

Malaria is a preventable and treatable disease. 

  • It is a public health problem today in more than 100 countries inhabited by some 2.4 billion people -- 40 percent of the world's population.

  • Malaria is estimated to cause 300- 500 million clinical cases and over one million deaths each year.

  • Every 30 seconds, a child somewhere dies of malaria. In any given year, nearly ten percent of the global population will suffer a case of malaria.

  • Children are especially vulnerable to malaria. In Africa, where 80% of malaria cases are treated at home, the disease kills one child in twenty before the age of five.

  • Pregnant women are also at high risk. They have an increase risk of disease and death, as well as adverse impacts for their developing babies- including low birth weight, growth retardation, still births and death.

  • In African countries, up to 60% of hospital admissions may be for malaria; that's 6 out of 10 admissions!

  • Travelers to Sub-Saharan Africa have the greatest risk of both getting malaria and dying from their infection. All travelers to any countries with malaria risk may get this potentially deadly disease, and thus taking proper precautions is essential.

  • Other high-risk groups include refugees, displaced persons, or labour forces entering into endemic areas.

  • Malaria is transmitted in large areas of Africa, Central and South America, the island of Hispaniola (includes Haiti, Jamaica and the Dominican Republic), Asia (including the Indian subcontinent, Southeast Asia and the Middle East), Eastern Europe, and the South Pacific.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Contact Information